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L

oss of proliferative control is a deﬁning feature of human cancer. Most cancer cells
develop cell-intrinsic mechanisms of supplying growth-stimulatory signals as well as
disrupting the response to cell cycle arrest cues (1). To this end, mutations in the
retinoblastoma protein (RB) pathway are central to disrupting proliferative control in
tumorigenesis (2–4). Deletion of the RB1 gene prevents cell cycle arrest in response to
a broad range of signals (3). Similarly, overexpression or hyperactivation of D-type
cyclins and their associated cyclin-dependent kinases (CDKs) can lead to constitutive RB
phosphorylation and cell cycle entry. Finally, deletion or promoter methylation of
CDKN2A that encodes the CDK inhibitor p16 serves to deregulate kinase activity,
causing constitutive phosphorylation of RB. Cancer cell genomes that sustain a single
mutation in this pathway are considered to have disrupted RB pathway function and
are deﬁcient for cell cycle control (3, 5, 6). Historically, this concept of RB pathway
inactivation suggested that mutations in different components of the pathway are
relatively equivalent and that additional mutations provide no subsequent advantage
to cancer progression (2, 3, 6, 7).
A number of recent clinical observations challenge the logic of single RB pathway
mutations in cancer. First, multiple studies have shown that RB1 loss is speciﬁcally
predictive of a favorable response to chemotherapy (8–11), whereas p16 expression or
overall proliferative rates are not (8–10). This suggests that RB pathway mutations are
not necessarily equivalent. Second, a number of studies have suggested that RB1 gene
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ABSTRACT Proliferative control in cancer cells is frequently disrupted by mutations
in the retinoblastoma protein (RB) pathway. Intriguingly, RB1 mutations can arise
late in tumorigenesis in cancer cells whose RB pathway is already compromised by
another mutation. In this study, we present evidence for increased DNA damage and
instability in cancer cells with RB pathway defects when RB1 mutations are induced.
We generated isogenic RB1 mutant genotypes with CRISPR/Cas9 in a number of cell
lines. Cells with even one mutant copy of RB1 have increased basal levels of DNA
damage and increased mitotic errors. Elevated levels of reactive oxygen species as
well as impaired homologous recombination repair underlie this DNA damage.
When xenografted into immunocompromised mice, RB1 mutant cells exhibit an elevated propensity to seed new tumors in recipient lungs. This study offers evidence
that late-arising RB1 mutations can facilitate genome instability and cancer progression that are beyond the preexisting proliferative control deﬁcit.
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RESULTS
Spontaneous DNA damage in RB1-deﬁcient cancer cells. To investigate RB1
deﬁciency in RB pathway-disrupted cells, we utilized a number of cell lines that are
reported to be defective for p16, the product of the CDKN2A gene, or that possess
activation of cyclin D/CDK4. Initially, we used p16-deﬁcient U2OS cells (28) and Cas9
with guide RNA (gRNA) pairs that target exon 22 of RB1 because loss of this exon
creates null alleles in cancer (29). Cells were transfected with plasmids to deliver pairs
of gRNAs and Cas9 (or the D10A mutant). Following transient drug selection, colonies
were isolated, expanded, and genotyped by PCR to search for RB1 deletions (Fig. 1A).
Candidates were rigorously selected by checking RB expression by Western blotting
(Fig. 1B), ensuring that heterozygous clones were not mixtures of wild-type and
knockout cells using ﬂuorescent RB staining (Fig. 1C), and conﬁrming that the most
likely off-target sites were not mutated (Table 1). Using this approach, we selected four
clones each for wild-type and knockout RB1 genotypes and three clones for the RB1⫹/⫺
genotype, which were used in subsequent experiments.
To determine if RB1 mutation status affects genome stability in these engineered
cell lines, DNA damage was assessed in untreated, proliferating cells by staining for
␥H2AX. Foci were visualized by immunoﬂuorescence (IF) microscopy, and images were
captured using confocal microscopy (Fig. 1D). The quantity of foci per nucleus was
determined, and this revealed a signiﬁcant increase in ␥H2AX in the knockout and
heterozygous lines compared to those that are wild type for RB1 (Fig. 1E).
We quantiﬁed the abundance of ␥H2AX foci in additional RB pathway mutant cell
lines to determine if increased DNA damage is a common consequence of RB loss. We
August 2019 Volume 39 Issue 16 e00105-19
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loss is more prevalent in advanced cancers or mechanistically contributes to progression or dissemination (12–15), a stage where cell-autonomous proliferative control is
presumably already deregulated. Collectively, these examples suggest that RB1 mutation contributes more to tumor progression than just alterations to proliferative control
and that RB1 loss may confer other cancer-relevant characteristics. Remarkably, some
studies even highlight that single-copy loss of RB1 may be functionally signiﬁcant (12,
16–18).
Beyond RB’s role in cell cycle control through E2F transcriptional regulation, it has
been reported to participate in a host of functions that contribute to genome stability
(19). These include chromosome condensation through RB-dependent recruitment of
condensin II and cohesin (20, 21). The RB protein also inﬂuences the repair of DNA
breaks through both nonhomologous end joining (NHEJ) (22) and homologous recombination (HR) (23) and through induction of mitochondrial biogenesis that impacts cell
metabolism (24–26). Some of these functions, such as repair of DNA breaks by HR, are
obligatorily outside RB’s role in G1-to-S-phase regulation. In addition, other roles, such
as effects on mitochondrial biogenesis and metabolism, take place in proliferating
populations of cells, further suggesting that this is independent of G1/S regulation and
the RB pathway. It is noteworthy that some atypical RB functions in genome stability,
or late-stage cancer progression, may be sensitive to single-copy loss (16–18, 27). Thus,
the existence of shallow RB1 deletions may indicate that RB’s less-well-appreciated
functions in genome stability could underlie cancer-relevant characteristics that are
independent of classical RB pathway function in cancer (7).
In order to test if RB1 loss is relevant to cancer cells that already possess RB pathway
disruption, we induced mutations in RB1 using CRISPR/Cas9. These cells displayed
spontaneous DNA damage as evidenced by ␥H2AX foci and elevated levels of reactive
oxygen species (ROS). We also determined that RB1 mutations decreased the ability to
repair DNA breaks by homologous recombination, and this is supported by elevated
levels of anaphase bridges in mitosis. RB1 mutant cells were xenografted into immunocompromised mice, and this revealed similar growth kinetics in subcutaneous
implantation, with RB1-null cells showing a greater propensity to colonize lungs. These
experiments underscore the discovery that RB1 mutation in cells that already possess
RB pathway disruption creates DNA damage and fuels cancer progression.

Molecular and Cellular Biology

FIG 1 CRISPR/Cas9-induced mutations in RB1 cause DNA damage. (A) Ethidium bromide-stained agarose gel
showing examples of wild-type, heterozygous, and homozygous mutant RB1 genotypes that are detected by PCR
ampliﬁcation of exon 22 sequences. MW, molecular weight. (B, top) Representative Western blot showing RB
expression in control, heterozygous, and homozygous mutant cells. (Bottom) Sp1 loading control. (C) Immunoﬂuorescence microscopy was used to detect RB expression (green) in cultures of control, heterozygous, or homozygous mutants. Cells were counterstained with DAPI to visualize nuclei (blue). (D) Representative confocal microscopy images of ␥H2AX foci (red) in control, heterozygous, and homozygous RB1 mutant cells. Cells were
counterstained with DAPI to visualize nuclei (blue). (E) Counts of ␥H2AX foci for each of the U2OS RB1 genotypes.
The average proportions of cells with discrete numbers of foci are shown as histograms, while the cumulative
frequency of foci for each genotype is shown in the inset. The average distributions of foci for RB1 wild-type (4
different clones), heterozygous (3 different clones), and knockout (4 different clones) cells were compared using the
Kolmogorov-Smirnov test (*, P ⬍ 0.05). (F) U2OS cells were transfected with CRISPR/Cas9 constructs targeting either
a safe-harbor site in the genome or exon 2 of the RB1 gene. Three clones were selected under both control and
knockout conditions, and ␥H2AX foci were quantiﬁed by ﬂuorescence microscopy. The average proportions of
␥H2AX foci for both RB1 wild-type and knockout genotypes are shown as histograms, while the cumulative relative
frequency of foci is shown in the inset. Focus distributions were again compared by a Kolmogorov-Smirnov test.
(G) H460 lung cancer cells were stained for ␥H2AX foci and analyzed as described above for panel F. (H) H1792
non-small cell lung cancer cells were analyzed as described above for panel F. All error bars are ⫹1 standard error
of the mean (SEM). *, P ⬍ 0.05.
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TABLE 1 Characterization of the U2OS RB1 mutant clones generated by targeting
exon 22a
Off-target genotyped
b

Clone
U2OS

Cas9 form
NA

RB1 genotype
Wild type

21B2

D10A

Wild type

21B4

D10A

Wild type

11B5

D10A

Wild type

4C1

D10A

Heterozygous

21D5

D10A

Heterozygous

21A1

D10A

Heterozygous

12C3

D10A

Null

5A5

WT

Null

6B1

WT

Null

5C4

WT

Null

c

Predicted protein
WT
WT
WT
WT
WT
WT
WT
WT
WT
p.Y771fsX8
WT
p.Q770HdelX10
WT
p.I753delX12
p.I752IfsX9
p.E748CdelX11
p.N757TX31
p.P776VdelX6
p.Y756YfsX14
p.S751SfsX10
p.S773FfsX14
p.Y756delX

ALDH1L1
NA

ZNF699
NA

ND

ND

WT

WT

ND

ND

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

aNA,

not applicable; ND, not determined; WT, wild type.
were determined by PCR and sequencing.
cAmino acid coding changes were predicted based on nucleotide sequences.
dThe top-scoring off-target intragenic locations determined for each gRNA, ZNF699 for gRNA X22B and
ALDH1L1 for gRNA X22C, were also sequenced to probe for unwanted mutations.

used cells that were modiﬁed with control nontargeting gRNAs or that were produced
by targeting exon 2 of RB1. RB deﬁciency in these cells was conﬁrmed by Western
blotting (data not shown). Using RB1-null U2OS cells produced in this manner, we again
observed increased quantities of ␥H2AX foci in RB-deﬁcient cells compared to their
controls (Fig. 1F). In addition, clones of control and RB1 knockout NCI-H460 (CDKN2Adeleted) and NCI-H1792 (CDK4-ampliﬁed) lung cancer cells also displayed differences in
spontaneous DNA damage (Fig. 1G and H). This analysis demonstrated an elevation in
the number of ␥H2AX foci in each of the RB1-deleted lines.
To further investigate the source of DNA damage in RB1 mutant cells, we assessed
their sensitivity to a number of chemical agents to determine if speciﬁc stresses could
amplify defects that cause increased DNA damage. We tested aphidicolin (APH), a DNA
polymerase inhibitor that causes replication stress, and etoposide, a topoisomerase
inhibitor that creates DNA double-stranded breaks. Hydrogen peroxide (H2O2) was used
to induce oxidative damage, and cisplatin was used to create interstrand cross-links,
among other damaging effects. Representative U2OS clones of each genotype were
treated for 72 h with a range of chemical concentrations, after which alamarBlue was
used to quantitate the cytotoxicity of each agent. These assays revealed that both
heterozygous and homozygous RB1 mutations sensitize cells to hydrogen peroxide and
cisplatin but not aphidicolin or etoposide (Fig. 2A to D). Because platinum therapeutics
preferentially beneﬁt patients with RB-deﬁcient cancers (8, 9), we also tested control
and RB1⫺/⫺ H460 and H1792 cells for their sensitivity to cisplatin. This revealed
increased sensitivity to cisplatin in H460 and H1792 cells upon RB1 deletion (Fig. 2E
and F).
Overall, these drug sensitivities suggest that oxidative damage may underlie some
aspects of the DNA damage phenotype in RB1 mutant cells. We compared ROS levels
in wild-type and RB1 mutant U2OS cells with and without H2O2 using an ROS indicator,
5(6)-carboxy-2=,7=-dichlorodihydroﬂuorescein diacetate (CA-DCF-DA). For both untreated and H2O2-treated cells, there was more ﬂuorescence of the ROS indicator in RB1
August 2019 Volume 39 Issue 16 e00105-19
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FIG 2 Cancer cells with RB1 mutations have elevated reactive oxygen species levels and sensitivity to
cisplatin. (A to D) Aphidicolin (A), etoposide (B), cisplatin (C), and hydrogen peroxide (D) were added to
cultures of the indicated genotypes of U2OS cells. Viability was assessed after 72 h using alamarBlue, and
dose-response curves were used to calculate IC50 values for each genotype. Both RB1 mutant genotypes
have signiﬁcantly lower IC50 values in response to cisplatin and hydrogen peroxide than control U2OS
cells (as determined by one-way ANOVA). (E and F) H460 and H1792 cancer cells with RB1 mutations were
treated with cisplatin as described above for panel C. Differences in IC50 values were determined using
a paired t test. (G) To detect ROS, CA-DCF-DA was added to culture medium at the end of 72 h of mock
or hydrogen peroxide treatment. Normalized ﬂuorescence was averaged for four clones of RB1 wild-type
and knockout genotypes and for three clones for the heterozygous genotype. Mean values were
compared by two-way ANOVA. (H) Cells were ﬁxed and stained for 8-oxoG and DAPI and visualized by
ﬂuorescence microscopy. The average 8-oxoG signal per nucleus was determined using ImageJ, with
DAPI staining deﬁning the nuclear area. Three clones per genotype were used, and data were normalized
to the mean signal from RB1 wild-type cells in duplicate experiments. Statistical signiﬁcance in staining
intensity was determined by Kruskal-Wallis one-way analysis of variance and Dunn’s multiple-comparison
test. (I) 53BP1 foci were quantitated for each RB1 genotype using Focinator as with ␥H2AX. No signiﬁcant
differences were observed, as determined by the Kolmogorov-Smirnov test. At least 120 cells from one
U2OS clone were analyzed in duplicate experiments for each RB1 genotype. All error bars are ⫾1 SEM.
*, P ⬍ 0.05.

mutant cells, as RB1⫺/⫺ and RB1⫹/⫺ cells were equivalent (Fig. 2G). We also ﬁxed and
stained cells for 8-oxoguanine (8-oxoG), one of the most abundant lesions resulting
from oxidative modiﬁcation of DNA (30), and quantiﬁed the staining in 4=,6-diamidino2-phenylindole (DAPI)-deﬁned nuclear areas using ImageJ (31). Control U2OS values
were used to normalize the 8-oxoG signal from RB1 mutants. Again, both RB1⫹/⫺ and
RB1⫺/⫺ U2OS cells had more 8-oxoG staining than did RB1⫹/⫹ cells (Fig. 2H).
These experiments indicate that loss of RB1 in cells with preexisting RB pathway
defects increases basal levels of DNA damage. Reactive oxygen species appear to be
one source of this damage. A chemical agent that directly induces breaks (etoposide)
did not selectively affect RB1 mutant cells; however, sensitivity to a DNA cross-linking
agent (cisplatin) suggests a potential inability to repair DNA damage by homologous
recombination. Both observations are consistent with a lack of 53BP1 foci, a marker of
August 2019 Volume 39 Issue 16 e00105-19
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NHEJ, in RB1 mutant U2OS cells compared to controls (Fig. 2I). This suggests that the
nature of DNA damage marked by ␥H2AX in these RB1 mutant cells is not necessarily
double-stranded DNA breaks and that NHEJ is not the dominant pathway to repair
damage in these cells. Overall, these experiments indicate that RB1 loss contributes to
an unstable genome, regardless of the proliferative control status of the cell.
RB1 mutant cells have randomly distributed DNA damage. To further understand spontaneous DNA damage in RB1 mutant U2OS cells, we sought to determine if
damage occurred at speciﬁc locations within the genome. We performed chromatin
immunoprecipitation sequencing (ChIP-Seq) to identify DNA sequences associated with
␥H2AX as well as histone H4 as a control. Because spontaneous damage in untreated
cell cultures is relatively rare, we pooled chromatin from 20 separate ␥H2AX ChIP
experiments per genotype to create each sequencing library (Fig. 3A to E). We determined peak locations and numbers using model-based analysis for ChIP-Seq (MACS)
(32), and the quantities of ␥H2AX and H4 peaks were similar between genotypes (Fig.
3A). Looking at a large region of chromosome 4 as a representative view of the
genome, we did not observe consequential differences between genotypes for ␥H2AX
or H4 peaks (Fig. 3B). Since peak ﬁnding at a genome scale failed to indicate obvious
locations of DNA damage enrichment, we investigated individual genome sequence
categories in search of elevated ␥H2AX deposition. The proportions of aligned ␥H2AX
ChIP-Seq reads per million mapped reads versus input reads for each of the genotypes
were compared within each repetitive element category and log2 transformed for
display as a heat map (Fig. 3C). Some categories, such as short interspersed nuclear
elements (SINEs) and multicopy genes, appear to have slight enrichment of ␥H2AX
localization in RB1⫹/⫺ and RB1⫺/⫺ compared to RB1⫹/⫹ cells based on color, but a
two-tailed one-sample t test with false discovery rate (FDR) multitest correction did not
score these as signiﬁcant. Therefore, even within repetitive sequences in the genome,
there does not seem to be an enrichment of ␥H2AX within RB1 mutant cells compared
to controls.
Previous studies suggest that ␥H2AX levels can be elevated at common fragile sites
(CFS) of cancer cells under standard cell culture conditions because of replication stress
(33). To investigate these locations, we quantiﬁed the number of ␥H2AX ChIP-Seq
reads, scaled them to the proportions of total aligned reads, and normalized them to
input levels. RB1⫹/⫺ and RB1⫺/⫺ cells were compared to the wild type using a
two-tailed one-sample t test. This analysis revealed 23 CFS that had more ␥H2AX
alignments than the wild type and 24 CFS that had signiﬁcantly fewer in RB1 mutant
cells than in controls (Fig. 3D). Figure 3E shows examples of CFS locations with the
greatest increase in ␥H2AX in RB1 mutants (FRA2E), the greatest reduction in ␥H2AX in
RB1 mutants (FRA6G), and unchanged ␥H2AX levels (FRA6D). These examples appear
highly similar between genotypes. Overall, it is possible that the distribution of ␥H2AX
within each CFS is shifting slightly between the mutants and the wild type. However,
there does not appear to be more of a bias in general for ␥H2AX elevation at CFS in RB1
mutant cells.
Collectively, our analysis of ␥H2AX distribution across the genome suggests that
there is no particular chromosome location or sequence category that is preferentially
enriched for this mark of DNA damage. These data suggest that the increase in ␥H2AX
foci observed in RB1⫹/⫺ and RB1⫺/⫺ cells is likely due to an overall increase in DNA
damage and not newly arising locations, or “hot spots,” of damage. This is in contrast
to primary cells with a normal RB pathway that experience RB loss and preferentially
damage centromeric repeats (16). The elevated sensitivity to peroxide and cisplatin and
increased ROS and 8-oxoG levels are consistent with DNA damage being randomly
located in RB1 mutant U2OS cells.
Homologous recombination repair defects in RB1-deﬁcient cancer cells. Another potential source of intrinsic DNA damage could arise from defective repair. For
this reason, we investigated the efﬁciency of HR and NHEJ repair using ﬂuorescent
reporters (34, 35). In this assay, a promoterless, but functional, green ﬂuorescent protein
August 2019 Volume 39 Issue 16 e00105-19
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FIG 3 ␥H2AX is randomly distributed in the genomes of RB1 mutant cells. (A) Total number of MACS peaks found for H4 control
and ␥H2AX ChIP-Seq reads for the indicated genotypes. (B) A 20-Mb region of chromosome 4, with ChIP-Seq read alignments
for ␥H2AX and H4. Tracks were normalized by subtracting input reads. Blue indicates more reads in the ChIP versus the input,
and red indicates fewer reads. (C) Determination of numbers of ChIP-Seq reads mapping to repetitive sequences as well as unique
genome regions. The heat map shows the log2 ratios of the abundances of ␥H2AX-precipitable reads per million mapped reads
versus the input for each of the respective genotypes at each element analyzed. LTR, long terminal repeat; SINEs, short
interspersed nuclear elements; LINEs, long interspersed nuclear elements. (D) Aligned ␥H2AX ChIP-Seq read proportions within
common fragile sites (CFS) were ﬁrst normalized to their respective inputs, and RB1⫹/⫺ and RB1⫺/⫺ values were then normalized
to wild-type (WT) values and log2 transformed. A two-tailed one-sample t test was performed to determine if the normalized
mean read count proportions of the RB1 mutants at the various CFS are equal to the normalized read count proportions of the
corresponding CFS in the wild type. CFS where the false discovery rate was less than 0.1 were grouped according to whether
there were signiﬁcantly more alignments in the RB1 mutants or signiﬁcantly more alignments in the RB1⫹/⫹ sample. There is no
signiﬁcant difference between these two categories (determined by an unpaired t test). FRA2E had the most reads in RB1⫹/⫺ and
RB1⫺/⫺ cells compared to the control, while FRA6G had the most reads in the wild type compared to the mutants. Error bars are
⫾1 SEM. (E) ChIP-Seq tracks for ␥H2AX and H4 at representative CFS. FRA2E and FRA6G from panel D are shown, while FRA6D
had no change in the proportion of ␥H2AX reads that aligned between the genotypes. Regions of signiﬁcant enrichment (MACS
peaks) are denoted by yellow bars.
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FIG 4 Defective homology-directed repair of DNA breaks in RB1 mutant cells. (A) Schematic of the DR-GFP
homology-directed repair construct used. Cleavage of an I-SceI site integrated into an expressed, but mutant, GFP
gene (SceGFP) can be repaired from a downstream internal GFP fragment (iGFP). (B) U2OS cells with clonal
integration of the HR reporter construct were ablated for RB1 expression with lentiviral delivery of Cas9 and an
RB1-speciﬁc sgRNA. The relative expression of RB in the population of cells was determined by Western blotting,
and Sp1 serves as a loading control. (C) HR repair efﬁciency of RB1 mutant U2OS cells was determined by
transfecting an expression vector for I-SceI endonuclease (⫹), or a relevant negative-control expression vector, and
quantitating PI-negative (PI⫺) and GFP-positive (GFP⫹) cells by ﬂow cytometry (n ⫽ 5). All error bars are ⫾1 SEM.
*, P ⬍ 0.05. (D) Schematic of the EJ5 NHEJ reporter system. DNA breaks at tandem I-SceI sites release the puromycin
resistance gene, allowing NHEJ repair to join a promoter to the GFP-expressing sequence. (E) After the generation
of a stable U2OS clone containing the NHEJ reporter construct, RB1 was deleted as described above and conﬁrmed
by Western blotting. (F) NHEJ repair efﬁciency was determined by transfecting an I-SceI endonuclease expression
vector (⫹), or the negative control, and PI-negative and GFP-positive cells were quantitated by ﬂow cytometry
(n ⫽ 3). (G) RT-qPCR was performed to assess the transcript levels of various HR factors in RB1 wild-type (4 different
clones), heterozygous (3 different clones), and knockout (4 different clones) cells. Statistical differences in means
were determined by one-way ANOVA. All error bars are ⫾1 SEM. *, P ⬍ 0.05. (H) Western blots showing expression
of various HR factors in wild-type, heterozygous, and homozygous RB1 mutant clones. The Sp1 loading control is
shown on the bottom.

(GFP) is used to repair an adjacent break induced in a mutant, expressed, form of the
GFP gene (Fig. 4A). We generated clonal U2OS lines bearing this reporter and created
a population of cells deleted for RB1 with lentiviral delivery of Cas9 and an RB1-speciﬁc
gRNA (Fig. 4B). Introduction of the restriction enzyme I-SceI into these cells induced
breaks, and RB1-deﬁcient cells were defective for their repair (Fig. 4C). Similarly, we
generated U2OS clones that stably maintain an NHEJ reporter for repair of an induced
break that links a constitutive promoter with a GFP gene. Loss of RB expression was
again conﬁrmed by Western blotting (Fig. 4E), and induction of breaks was used to test
August 2019 Volume 39 Issue 16 e00105-19
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repair in an RB1-deﬁcient background (Fig. 4F). This failed to reveal a defect in repair,
suggesting that RB1 loss in U2OS cells speciﬁcally reduces HR repair.
To investigate if this reduction in HR repair is related to changes in the expression
of HR factors due to RB1 loss, we examined DNA damage repair genes that are known
to be regulated by E2Fs (36, 37). Of these candidates, only one gene, RPA2, was seen
to have signiﬁcantly lower transcript levels in RB1⫺/⫺ U2OS cells (Fig. 4G). However,
when protein levels of a subset of these factors, including RPA2, were investigated, no
changes in expression between genotypes were evident (Fig. 4H). This suggests that
the expression levels of key HR factors are not changed in these cells as a result of RB1
loss.
To assess how RB1 mutant U2OS cells respond to DNA breaks, each genotype was
exposed to 2 Gy of gamma irradiation (␥IR). Cells were ﬁxed and stained for ␥H2AX and
DAPI to measure the amount of DNA damage. One hour after ␥IR, despite pronounced
␥H2AX foci in all genotypes, the amount of DNA damage was signiﬁcantly larger in
RB1⫺/⫺ clones than in heterozygous or wild-type cells (Fig. 5A). After 24 h, most of the
DNA damage was repaired, and the RB1⫺/⫺ cells retained more ␥H2AX foci than cells
of the other two genotypes (Fig. 5B). This same increase in DNA damage in the RB1-null
background was seen in H460 cells (Fig. 5C and D) and in H1792 cells (Fig. 5E and F),
both 1 h and 24 h after exposure to 1 Gy of ␥IR. Overall, this indicates that cells
completely lacking RB are more sensitive to ␥IR, likely because they are not able to
repair DNA breaks as efﬁciently by HR repair.
Next, we investigated the ﬁdelity of mitosis to determine if the elevated levels of
DNA damage and impaired HR repair impacted chromosome segregation and aneuploidy (38). Flow cytometry was performed on RB1-deﬁcient cells that were labeled and
stained with bromodeoxyuridine (BrdU) and propidium iodide (PI) (39). This analysis
failed to show statistically different changes in cell cycle phases between the different
genotypes (Fig. 6A). However, when DNA content greater than 4N was analyzed, there
was a signiﬁcant difference between wild-type and RB1 knockout cells, with RB1⫹/⫺
cells showing an intermediate value (Fig. 6B). This suggests that mitotic errors in these
cells may lead to aneuploidy.
To further investigate mitotic defects and their relationship with DNA damage and
replication stress, cells were stained with DAPI and antibodies to Bloom syndrome
protein (BLM) to visualize chromosome bridges, and mitotic ﬁgures were imaged using
confocal microscopy (Fig. 6C). We observed abundant chromosome bridges in RB1⫺/⫺
and RB1⫹/⫺ mutant cells (Fig. 6D). In the RB1 mutants, there were some ultraﬁne
bridges (UFBs), which are “threadlike” DNA structures that stain only with BLM (40). In
RB1⫹/⫺ anaphase cells, 5% (2/43) were seen to have UFBs, and in RB1⫺/⫺ cells, this was
increased to 8% (3/39), whereas in wild-type cells, UFBs were not observed (0/30).
However, the majority of BLM bridges were stained with DAPI, indicating that anaphase
bridges were most common. Anaphase bridges are known to occur in HR-defective
cells, while UFBs can be induced by replication stress (38).
Finally, to investigate the link between UFBs in the RB1 mutant cells and a possible
increase in replication stress, we performed a nucleoside supplementation assay and
investigated changes in DNA content and DNA damage as surrogate markers for
nucleoside suppression of replication stress. Flow cytometry of cells stained with
propidium iodide was performed 48 h after medium replacement, either with or
without the addition of nucleosides. This analysis failed to show statistically different
changes in ⬎4N DNA content within genotypes when comparing the different nucleoside treatment groups, although there was a trend toward decreased aneuploidy after
nucleoside supplementation for all genotypes (Fig. 6E). However, when we looked at
DNA damage of cells grown in parallel, RB1⫺/⫺ cells treated with 50 M nucleosides
had a signiﬁcant reduction in ␥H2AX foci compared to untreated knockout cells
(Fig. 6F). Nevertheless, this reduction in DNA damage after nucleoside supplementation
is modest and did not restore the levels of ␥H2AX foci to those seen in the RB1⫹/⫹
controls.
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FIG 5 Defective repair of ␥IR-induced DNA damage in RB1 knockout cells. (A and B) U2OS cells were treated
with 2 Gy ␥IR, ﬁxed 1 h (A) or 24 h (B) after treatment, and stained for ␥H2AX. Three clones per genotype
were used, and ␥H2AX foci were quantiﬁed. The proportions of cells with discrete numbers of foci are
shown as histograms, while the cumulative frequency of foci is shown in the inset. Differences in the
distributions of foci were determined using the Kolmogorov-Smirnov test. A green asterisk indicates that
RB1⫺/⫺ is statistically different from the other genotypes, while a black asterisk indicates that all genotypes
are statistically signiﬁcantly different from each other. (C and D) H460 cells were treated with 1 Gy ␥IR, ﬁxed
1 h (C) or 24 h (D) after treatment, and stained for ␥H2AX. (E and F) H1792 cells were treated with 1 Gy ␥IR,
ﬁxed 1 h (E) or 24 h (F) after treatment, and stained for ␥H2AX. All error bars are ⫹1 SEM. *, P ⬍ 0.05.

Taken together with experiments described above, defects in mitosis are best
characterized as anaphase bridges that cause aneuploidy. These types of errors are
consistent with HR repair deﬁciency and sensitivity to a DNA cross-linking agent such
as cisplatin. It appears that ␥H2AX foci can be suppressed slightly in RB1⫺/⫺ cells with
nucleosides, and RB1⫺/⫺ cells exhibit some UFBs, implying that they experience modest
DNA replication stress. However, the lack of sensitivity to aphidicolin and the lack of
increased ␥H2AX deposition at repetitive genome regions argue that replication stress
in these cells is quite modest. Overall, our analysis of mitotic errors is consistent with
a defect in HR repair being the main source of chromosome bridges in anaphase of
these RB1 mutant cells.
Increased lung metastases in RB1 mutant xenografts. To further characterize the
effects of induced RB1 mutations in cells that already possess RB pathway defects, we
performed xenograft experiments to determine if new cancer-relevant properties arise
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FIG 6 Increased mitotic errors in RB1 mutant cells. (A) BrdU and propidium iodide staining followed by
ﬂow cytometry was used to determine the cell cycle phase distribution of asynchronous cultures of U2OS
cells. Four clones for the wild-type and knockout genotypes and three clones for the heterozygous
genotype were analyzed. (B) Flow cytometry analysis showing the proportion of cells with ⬎4N DNA
content. Means were compared using one-way ANOVA. (C) Cells in anaphase were imaged by ﬂuorescence microscopy using DAPI (blue) and BLM (red) in cells from each RB1 genotype. Arrows indicate
anaphase bridges that are stained by both DAPI and BLM. (D) Quantitation of the numbers of anaphase
cells with DAPI-stained chromosome bridges. The proportion of cells with bridges is signiﬁcantly higher
in the knockout and heterozygous clones than in the wild-type clone, as determined by the 2 test. (E)
Representative clones from each RB1 genotype were either left untreated or treated with 10 M or 50 M
nucleosides for 48 h. Flow cytometry analysis of propidium iodide-stained cells shows the proportion of
cells with ⬎4N DNA content. Mean differences were compared by one-way ANOVA (n ⫽ 3). (F)
Nucleoside-treated cells were ﬁxed and stained for ␥H2AX after 48 h of culture. DNA damage is
summarized in frequency plots. The dotted line in the RB1⫹/⫺ and RB1⫺/⫺ cumulative frequency plots
represents the wild-type untreated cells. Statistical signiﬁcance between genotypes was determined by
the Kolmogorov-Smirnov test. All error bars are ⫾1 SEM. *, P ⬍ 0.05.

upon the loss of RB. We injected cells subcutaneously into immunocompromised mice
and allowed tumors to form for an 8-week period before analyzing growth by mass and
histology (Fig. 7A). This analysis revealed highly cellular tumors with abundant mitotic
activity and foci of necrosis. Cells appeared epithelioid, with no deﬁnite features of
osteoid differentiation, and they had small areas suggesting glandular differentiation.
This phenotype was consistent among all genotypes (Fig. 7B). Tumor masses were
determined at the endpoint and were not statistically different between genotypes,
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FIG 7 Increased lung metastases with RB1 mutant cells in xenograft experiments. (A) Illustration of
analysis of subcutaneous injections of RB1 mutant U2OS cells. Tumors were allowed to form for 8 weeks
before analysis of tumor mass and histology. (B) Representative H&E-stained tissue sections from each
genotype of tumor. (C) Tumor masses from subcutaneously injected cells. The means are not statistically
different. (D) Schematic of tail vein injections to study dissemination to the lungs. Mice were injected
with cells, and cell dissemination and proliferation were allowed to proceed for 8 weeks. Lungs were then
isolated, sectioned, stained with H&E, and analyzed using QuPath. (E) The percentage of lung area
occupied by cancer cells was calculated from tissue sections and averaged between mice. (F) Tumor cell
nodules were counted using the assistance of QuPath and averaged among recipient mice. (G) The
percent tumor cell burden was divided by the number of tumor nodules to determine the average tumor
cell area per nodule. Statistical signiﬁcance between genotypes was determined with a t test. All error
bars are ⫹1 SEM. *, P ⬍ 0.05.

with RB1⫺/⫺ cells even trending toward a smaller size (Fig. 7C). Mice were also tail vein
injected, and cell dissemination and proliferation were allowed to proceed for 8 weeks,
at which time lungs were harvested, ﬁxed, and sectioned. Hematoxylin and eosin
(H&E)-stained sections were digitally analyzed to quantitate cellular inﬁltration of U2OS
cells (Fig. 7D). This revealed a striking increase in RB1⫺/⫺ U2OS cells in the lungs of
these mice compared to control and RB1⫹/⫺ cells, as determined by the percentage of
the lung section area that is occupied by malignant cells (Fig. 7E). There were signiﬁcantly more individual nodules of RB1⫺/⫺ cells per lung than for the other genotypes
(Fig. 7F), further suggesting that RB1 loss increased the efﬁciency of dissemination or
establishment in the lung. Finally, the area occupied by tumor cells per nodule is lower
in both RB1 mutant genotypes, indicating that control cells form rarer, larger clusters of
cells, whereas RB1 mutants tend to seed more efﬁciently and perhaps proliferate more
slowly (Fig. 7G). We note that one mouse injected with RB1⫹/⫺ cells showed extensive
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dissemination and tumor burden that were highly reminiscent of mice injected with
RB1⫺/⫺ cells (Fig. 8A and B). To investigate this further, we extracted DNA from
parafﬁn-embedded tumor material from this mouse. PCR analysis was used to genotype
RB1 exon 22 in these cells (Fig. 8C). This conﬁrmed that these cells maintained their
wild-type RB1 allele, suggesting that they had not undergone loss of heterozygosity as
a means to acquire an RB1⫺/⫺ phenotype.
These xenograft experiments indicate that RB1 mutations in U2OS cells have little
effect on the growth rate of primary tumors. Interestingly, RB1⫺/⫺ cells are much more
efﬁcient in colonizing recipient mouse lungs, suggesting that in addition to the DNA
damage and genome instability phenotypes described above, RB1 loss in RB pathwaydeﬁcient cells imparts characteristics that enable cancer progression.
DISCUSSION
To test if RB1 loss impacts cancer cells that already possess mutations disrupting the
RB pathway, we used CRISPR/Cas9 to create nonfunctional RB1 alleles. Using ␥H2AX
staining of cells, we found that even within cells deﬁcient for one copy of RB1, there is
an increase in spontaneous DNA damage. Experiments that probe drug sensitivity of
RB1 mutant cells, along with ChIP-Seq analysis of ␥H2AX foci and analysis of DNA
damage repair pathways, suggest a complex picture of cellular defects. We did not
detect speciﬁc hot spots of DNA damage, but sensitivity to peroxide and cisplatin
suggests that oxidative damage may cause sporadic DNA damage, as levels of reactive
oxygen species are elevated in RB1-deﬁcient cells. Mutant RB1 cells also have more
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FIG 8 Single-copy loss of RB1 can create cancer-enabling phenotypes. (A) H&E staining of lung tissue with the
highest number of RB1⫹/⫺ seeding events. (B) QuPath coloring to denote tumor tissue within these lungs (red). (C)
DNA was extracted from nodules of tumor cells in parafﬁn-embedded tissue containing these RB1⫹/⫺ cells or an
RB1⫹/⫹ control. PCR was performed to amplify exon 22 from recovered DNA and controls isolated from cell culture
to verify the ﬁnal genotype of cells in this sample. (D) The 10 most prevalent cancers were analyzed for RB1 gene
alterations using TCGA and Pan-Cancer Atlas data, using cBioPortal. A deep deletion is consistent with biallelic loss
of RB1, whereas a shallow deletion is suggestive of heterozygous RB1 deletion.
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abnormal mitoses characterized by anaphase bridges, reporter assays detect defects in
HR repair, and nucleoside supplementation in culture medium suppresses ␥H2AX foci,
suggesting additional endogenous sources of damage. Overall, this study reveals that
RB1 mutations lead to increased DNA damage that may enhance cancer progression.
The DNA damage phenotype caused by either single-copy or homozygous mutation
to RB1 is unlikely to be attributable to a single root cause, and we expect that RB1
deﬁciency may affect DNA damage in different cancer cells in various ways. We report
that RB1 deletion compromises HR repair but not NHEJ, and this is consistent with one
previous report (23) but contradicts another (22). Given that we observe more than 70%
of U2OS cells incorporating BrdU in a brief pulse, they are likely biased toward HR repair
pathways because of their cell cycle position. This is consistent with ␥H2AX foci not
being accompanied by 53BP1, and the activity levels of NHEJ reporters being almost an
order of magnitude lower than HR values, suggesting that U2OS cells are primed to use
the HR repair pathway, and thus, phenotypes in these cells reﬂect this reality. We expect
that the DNA damage and defective repair described in this report are relevant to
cancer progression phenotypes because graded differences between RB1 wild-type,
heterozygous, and homozygous genotypes are reﬂected in 8-oxoguanine abundance,
aneuploidy, and anaphase bridges. This stepwise trend in severity of phenotype in the
molecular alterations resulting from RB1 loss is similarly evident in the behavior of
RB1⫹/⫹, RB1⫹/⫺, and RB1⫺/⫺ mutant tail vein xenograft experiments, suggesting that
this increase in metastatic burden is related to a stepwise increase in DNA damage
experienced by these different genotypes.
Single-copy loss of RB1 may contribute to cancer in a number of ways. Primary
RB1⫹/⫺ cells from a number of sources are prone to mitotic errors (16–18), and
precursor lesions to retinoblastoma are characterized by aneuploidy (41), suggesting
that this is an early step in this disease. Therefore, partially defective RB1 can contribute
to the early stages of cancer through a distinct set of effects. However, a number of
studies have highlighted that RB1 loss is statistically enriched in advanced stages of
cancer progression (12–14). In addition, analysis of the landscape of cancer alterations
in The Cancer Genome Atlas (TCGA) consortia reveals that so-called “shallow deletions”
of RB1 are relatively commonplace (Fig. 8D), and these events are unlikely to be
explained by random, unselected events (42). From this perspective, our study offers a
critical proof of concept that late-stage loss of one copy of RB1 can create cancerenabling phenotypes in the host cell, even if it already possesses RB pathway mutations. Complete elimination of RB1 has a stronger effect on DNA damage phenotypes
and dissemination to the lungs, as demonstrated in this study; however, highly abundant single-copy RB1 loss may represent a mutational compromise in which advantageous phenotypes are acquired with an economy of mutational changes (43).
A number of studies correlate the absence of RB expression with improved patient
survival following treatment that includes platinum-based chemotherapy (8, 9). Loss of
RB correlated with improved survival of patients with lung adenocarcinomas treated by
resection and adjuvant cisplatin or carboplatin and a vinca alkaloid (8). More recently,
patients with high-grade serous ovarian cancer (HGSC) who experienced exceptionally
good clinical outcomes were studied (9). These patients were treated with platinumbased agents, and loss of RB was associated with long-term survival. From this
perspective, U2OS cells engineered to be deﬁcient for RB1 demonstrate that RB loss
increases sensitivity to cisplatin. Given that RB1 mutant cells were not more sensitive to
another agent that induces DNA breaks, etoposide, we interpret RB1 deﬁciency to
create a unique sensitivity to cisplatin that may relate to defective HR and higher
endogenous ROS levels that create a highly speciﬁc sensitivity to this class of chemotherapy.
In conclusion, although there are many cancers that have mutations in the RB
pathway that spare the RB1 gene itself, further mutations to RB1 surprisingly create
cancer-relevant characteristics that may inﬂuence disease progression. The frequency
of shallow deletions of RB1 across many cancers suggests that disease progression may
select for these characteristics.
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Cell culture. U2OS cells and the resulting clones were grown in Dulbecco’s modiﬁed Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 50 U/ml penicillin, and
50 g/ml streptomycin. H460 and H1792 cells and the resulting clones were grown in RPMI 1640 medium
supplemented with 10% FBS, 2 mM L-glutamine, 50 U/ml penicillin, and 50 g/ml streptomycin. Cells
were grown at 37°C in humidiﬁed air containing 5% CO2.
Generation of RB1 deletions using CRISPR. For creation of RB1 deletions, single guide RNAs
(sgRNAs) targeting exon 22 of RB1 were selected by using the CRISPR design tool at http://crispr.mit.edu/
(44). The sgRNA sequences were as follows: 5=-CACCGTATTATAGTATTCTATAACT-3= (X22B-top), 5=-AAA
CAGTTATAGAATACTATAATAC-3= (X22B-bottom), 5=-CACCGAGGATACTTTTGACCTACCC-3= (X22C-top),
and 5=-AAACGGGTAGGTCAAAAGTATCCTC (X22C-bottom). The X22B and X22C guides were each cloned
into the pX459 plasmid (with wild-type Cas9; Addgene plasmid 48139) and the pX462 plasmid (with the
D10A mutant version of Cas9; Addgene plasmid 48141) Both plasmids contain a puromycin resistance
cassette. Cells were seeded at a density of 105 cells per well in a 6-well dish, and the next day, a total of
1 g per well of a 1:1 mix of X22B and X22C CRISPR plasmids (either pX459 or pX462) was transfected
by use of X-tremeGENE HP DNA transfection reagent (Roche). The next day, each well was replated onto
a 15-cm dish, and the day after that, cells were cultured in selection medium with 2 g/ml of puromycin
for 2 days. Following this, cells were grown in normal cell culture medium for approximately 12 days,
following which single colonies were picked from the 15-cm plates using mechanical detachment with
a pipette tip, placed into wells of a 48-well dish, and allowed to grow. Cells were further passaged onto
larger plates and genotyped using the following primers: X22F (5=-TTACTGTTCTTCCTCAGACATTCAA-3=)
and X22R (5=-GGATCAAAATAATCCCCCTCTCAT-3=). PCR products (445 bp for the wild-type band) were
run in an agarose gel, and individual bands were gel puriﬁed using a Sigma GenElute gel extraction kit
and sent for Sanger sequencing using the X22F and X22R primers described above. For clones with
multiple PCR products, bands were puriﬁed and sent for sequencing separately to determine individual
RB1 alleles in each clone. For alleles that could not easily be resolved by gel electrophoresis, PCR products
were cloned into vectors using either the TOPO TA cloning kit for sequencing (Invitrogen) or the
CloneJET PCR cloning kit (Thermo Scientiﬁc).
The top-scoring off-target intragenic locations determined for each gRNA using the CRISPR Design
tool were also sequenced to probe for mutations. gRNA X22B had a potential off-target site in ZNF699
(X22B_OT_ZNF699_F [5=-GTGCCCTAAAACACTGAGGGA-3=] and X22B_OT_ZNF699_R [5=-TTTATGATCAAC
AAGGACCAGAGC-3=]), while X22C has a potential off-target site in ALDH1L1 (X22C_OT_ALDH1L1_F
[5=-GCCACGCTATGCTTGTGATG-3=] and X22C_OT_ALDH1L1_R [5=-CACCCCAGAGAAGGGAACAC-3=]). PCR
products were gel puriﬁed as described above and sent for Sanger sequencing using their respective
primers.
Nuclear extracts were prepared from U2OS CRISPR clones of interest, and Western blotting was
carried out using previously described protocols (45). Antibodies raised against RB (clones G3-245 [BD
Pharmingen] and C-15 [Santa Cruz]) and Sp1 (clone H-225; Santa Cruz) were used for Western blotting.
Samples were Western blotted using standard techniques.
To generate additional RB1 knockout and control cell lines, sgRNAs targeting either exon 2 of RB1
(5=-GGAGAAAGTTTCATCTG-3=) or a gene desert region of the genome (5=-TGAGCCTATATTAATTGG-3=)
were utilized. The sgRNAs were cloned into the lentiCRISPR v2 vector (Addgene plasmid 52961), which
also encodes Cas9. To generate lentivirus, HEK293T cells were transfected with the sgRNA vector and a
1:1:1 mixture of lentiviral packaging constructs (Addgene plasmids 12251, 12253, and 8454) using
polyethylenimine transfection reagent. Twenty-four hours after transfection, the HEK293T medium was
replaced, and recipient cells (U2OS, NCI-H1792, and NCI-H460) were seeded for infection. The following
day, medium on the recipient cells was replaced with lentiviral medium, and Polybrene was added at a
ﬁnal concentration of 8 g/ml. A second infection was performed the next day. Infected cells were then
selected with 2 g/ml puromycin for 3 days. To generate isogenic clones, populations of knockout (or
control) cells were sorted using a ﬂuorescence-activated cell sorter (FACS) as single cells in 96-well plates
(BD FACSAria II) and allowed to grow for approximately 2 weeks. Colonies were then expanded and
screened for loss of RB by an immunoassay using the Simple Western system according to the
manufacturer’s instructions. Successful knockout clones were also genotyped to conﬁrm clonogenic
origin. Genomic DNA was extracted using the PureLink genomic DNA minikit (Invitrogen), and the region
surrounding the cut site was ampliﬁed by PCR using the following primers: X2F (5=-TCACAGAAGTGTTT
TGCTGCTT-3=) and X2R (5=-TTTGGTGGGAGGCATTTATGGA-3=). PCR products were puriﬁed using the DNA
Clean and Concentrator kit (Zymo Research) and sent for Sanger sequencing.
Fluorescence microscopy. Cells grown either on glass coverslips or in glass-bottom plates were
ﬁxed in phosphate-buffered saline (PBS) containing 4% paraformaldehyde for 10 min and then permeabilized with PBS– 0.3% Triton X-100 for 10 min at room temperature. The ﬁxed cells were blocked in
blocking buffer (PBS– 0.3% Triton X-100 with either 5% donkey or goat serum depending on the species
in which the secondary antibodies were raised) for at least 1 h at room temperature. Cells were then
incubated with primary antibody in blocking buffer at room temperature for 1 h or at 4°C overnight.
Antibodies raised against RB (clone G3-245; BD Pharmingen), ␥H2AX (clone JBW301; EMD Millipore),
53BP1 (H-300; Santa Cruz), and BLM (C-18; Santa Cruz) were used for IF. After 3 washes with PBS– 0.3%
Triton X-100, cells were incubated with secondary antibody diluted in blocking buffer for 1 h at room
temperature. Cells were washed twice with PBS– 0.3% Triton X-100, incubated with 100 ng/ml 4=,6diamidino-2-phenylindole (DAPI) in PBS– 0.3% Triton X-100 for 5 min, washed twice more with PBS– 0.3%
Triton X-100, and then washed once with PBS before mounting with Slowfade gold antifade mountant
(catalog number S36936; Thermo Fisher Scientiﬁc).
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For 8-oxoG staining, cells were ﬁxed and blocked as described above, washed with PBS– 0.3% Triton
X-100, and incubated in an RNase solution (0.2 mg/ml RNase A, 10 mM Tris-HCl [pH 7.5], 15 mM NaCl, and
0.1% Triton X-100 in 1⫻ PBS) for 1 h at room temperature. Cells were washed with PBS– 0.3% Triton X-100
and then incubated in 2 M HCl for 10 min at room temperature, followed by a rinse with 50 mM Tris-HCl
(pH 8.0). Cells were washed with PBS– 0.3% Triton X-100, primary antibody incubation was then
performed using anti-DNA/RNA damage antibody raised against 8-oxoG (clone 15A3, catalog number
ab62623; Abcam), and all subsequent steps were completed as described above.
For confocal microscopy of RB, ␥H2AX, and BLM, cells were examined on an Olympus FluoView
FV1000 confocal microscope system. For confocal microscopy of 53BP1, a Nikon A1R confocal microscope was used. For nonconfocal microscopy, images were acquired using a Zeiss Axioskop 40 microscope and a Spot ﬂex camera. Foci were quantiﬁed using Focinator (46), while overall staining intensity
in cells was quantiﬁed by using ImageJ (31).
Gamma irradiation of cells. Cells subjected to ␥IR were plated at 100,000 cells per well in 6-well
dishes with glass coverslips on the bottom. The next day, cells were exposed to a cobalt 60 source until
a dose of either 2 Gy or 1 Gy was received. Cells were placed back in the cell culture incubator until the
appropriate time point after treatment to ﬁx cells for IF.
NHEJ and HR repair assays. For the HR repair assay, pDRGFP was used, which was a gift from Maria
Jasin (Addgene plasmid 26475 [http://n2t.net/addgene:26475]; Research Resource identiﬁer [RRID],
Addgene_26475), and for the NHEJ assay, pimEJ5GFP was used, which was a gift from Jeremy Stark
(Addgene plasmid 44026 [http://n2t.net/addgene:44026]; RRID, Addgene_44026). pDRGFP was linearized
using EcoRV, and pimEJ5GFP was linearized using XhoI. These linearized fragments were then individually used for transfection using Lipofectamine 3000 transfection reagent (Invitrogen) into U2OS cells.
The next day, each well was replated onto a 10-cm dish, and a day later, cells were cultured in selection
medium with 2 g/ml of puromycin for 3 days. To isolate single-cell colonies, limiting dilutions were then
used to seed cells into 96-well plates. After approximately 3 weeks, wells with growth from single-cell
isolates were transferred to single wells of 12-well plates and after a few days were treated with
puromycin again to ensure that the selected clones still contained either the NHEJ or HR constructs.
To determine the reporter efﬁciency in the isolated clones, 2 sets of transfections were performed per
clone, again using Lipofectamine 3000 transfection reagent (Invitrogen). For the ﬁrst set of transfections,
each clone was transfected with a plasmid expressing the I-SceI endonuclease, pCBASceI, which was a
gift from Maria Jasin (Addgene plasmid 26477 [http://n2t.net/addgene:26477]; RRID, Addgene_26477),
and a blasticidin marker, pMSCV-Blasticidin, which was a gift from David Mu (Addgene plasmid 75085
[http://n2t.net/addgene:75085]; RRID, Addgene_75085). The second set of transfections was performed
with an empty backbone plasmid, pCAG-FALSE, which was a gift from Wilson Wong (Addgene plasmid
89689 [http://n2t.net/addgene:89689]; RRID, Addgene_89689), and pMSCV-Blasticidin. For both of these
transfections, the blasticidin resistance plasmid was used in a 1:3 ratio with the complementary plasmid.
The next day, each well was replated onto a 10-cm dish, and the day after that, cells were cultured in
selection medium with 10 g/ml of blasticidin for 1 week. GFP-positive cells were then quantiﬁed by ﬂow
cytometric (FACS) analysis. To prepare cells for FACS analysis, they were washed with PBS, trypsinized,
resuspended in culture medium, and washed twice with PBS. Cell pellets were then resuspended in
0.5 ml of ﬂow cytometry staining buffer with propidium iodide (0.05% sodium azide and 0.5% bovine
serum albumin [BSA] in 1⫻ PBS with 0.01 mg/ml propidium iodide). For each reporter construct, the
clone with the highest ratio of the GFP signal when transfected with pCBASceI to the GFP signal when
transfected with pCAG-FALSE was selected for future studies.
To introduce CRISPR constructs into selected clones for each repair reporter, lentivirus particles were
generated in HEK293T cells. Lentivirus was created for both lentiCRISPR v2 with no guide RNA inserted
and lentiCRISPR v2 with the X22B sgRNA sequences for RB1 (described above) inserted. lentiCRISPR v2
was a gift from Feng Zhang (Addgene plasmid 52961 [http://n2t.net/addgene:52961]; RRID, Addgene_52961). The X22B RB1 guide sequences were inserted into the lentiCRISPR v2 plasmid as previously
described (47, 48). Culture media containing lentiviral particles were transferred to appropriate U2OS HR
and NHEJ reporter clones for 48 h, followed by selection with 4 g/ml puromycin for at least 5 days.
The populations of U2OS HR and NHEJ reporter clones that were infected with lentiCRISPR v2
plasmids, either with or without the RB1 guide, were then transfected with both pCBASceI and
pMSCV-Blasticidin or pCAG-FALSE and pMSCV-Blasticidin, selected as described above, and analyzed by
FACS analysis to determine repair efﬁciency. These transfections were performed in the same transduced
population of cells, but for experimental replicates, the cells were seeded at different times and then
subsequently transfected with plasmids. Cells grown in parallel to the transfected cells were used to
prepare nuclear extracts for Western blotting.
Expression of HR factors. Total RNA from cells was isolated using TRIzol reagent according to a
standard protocol (Invitrogen). First-strand cDNA synthesis was performed using an iScript cDNA
synthesis kit (Bio-Rad). Isolated cDNA was used in reverse transcription-quantitative PCRs (qRT-PCRs)
with iQ SYBR green supermix (Bio-Rad), using the following primers: RPA2_F (5=-CGAAAGCTATGGCAGC
TCCT-3=), RPA2_R (5=-GGCTCGGGCTCTTGATTTCT-3=), RAD54B_ F (5=-GCGAGGGGATAGCTGGTTAC-3=),
RAD54B_R (5=-AGTCGTGACCGGCGAAAAT-3=), BLM_F (5=-GAGTCTGCGTGCGAGGATTA-3=), BLM_R (5=-AG
TGTTCTGGCTGAGTGACG-3=), RAD51_F (5=-AGCTGGGAACTGCAACTCAT-3=), RAD51_R (5=-CCACACTGCTC
TAACCGTGA-3=), RECQL_F (5=-AGAGAAAGCCTATGAAGCAAGGA-3=), RECQL_R (5=-GGCTTCTGCCGAACCT
CATA-3=), BRCA1_F (5=-CTGAAGACTGCTCAGGGCTATC-3=), BRCA1_R (5=-AGGGTAGCTGTTAGAAGGCTGG3=), XRCC2_F (5=-GCGATGTGTAGTGCCTTCCA-3=), XRCC2_R (5=-TTCAAGAATATCACCATGCACAGG-3=),
BRCA2_F (5=-AAGCACTCCAGATGGCACAAT-3=), BRCA2_R (5=-GGGTACACAGGTAATCGGCT-3=), RAD52_F
(5=-ATGCTTTGGACAGTGCCAGT-3=), RAD52_R (5=-ACATTCTGCTGCGTGATGGA-3=), GAPDH_F (5=-ATGACC
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ACAGTCCATGCCAT-3=), and GAPDH_R (5=-TTGAAGTCAGAGGAGACCAC-3=). The resulting target quantiﬁcation cycle (Cq) values were normalized to the value for glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) and then expressed as fold changes relative to the global wild-type mean.
Nuclear extracts were prepared from clones for Western blots, and the following antibodies were
used: RPA32 (catalog number A300-244A; Bethyl), RAD54B (catalog number ab83311; Abcam), BLM (C-18;
Santa Cruz), and RAD51 (catalog number ab63801; Abcam) antibodies.
Determination of IC50s. For 50% inhibitory concentration (IC50) assays, U2OS cells were seeded at
a density of 1,200 cells per well, and H460 and H1792 cells were seeded at a density of 1,500 cells per
well, in 96-well dishes. Twenty-four hours after plating cells, medium was replaced with medium
containing the drugs of interest at the appropriate concentrations. Technical triplicates were analyzed for
each biological replicate. Serial dilutions of stock solutions of aphidicolin (APH), hydrogen peroxide
(H2O2), etoposide, hydroxyurea (HU), and cisplatin were created so that a constant amount of drug was
added to the medium for each drug concentration used. After 72 h, alamarBlue was added to an amount
equal to 10% of the volume in the well (i.e., 10 l per well with 100 l of medium and drug). After 4 h
of incubation, cytotoxicity was measured using a Synergy H4 hybrid reader (BioTek, USA), using
excitation/emission wavelengths of 560 nm/590 nm. Values were corrected using a blank of medium and
alamarBlue only. The amount of ﬂuorescence of alamarBlue for each well of drug-treated cells was then
normalized to the ﬂuorescence value obtained for the untreated cells of the same technical replicate.
These normalized ﬂuorescence values relative to untreated cells were then analyzed using Prism. The
drug concentrations were log transformed, and the data were subsequently ﬁt to a curve using nonlinear
regression [log(inhibitor) versus response (three parameters)]. IC50 values were obtained from the best-ﬁt
values, and IC50 values from three biological replicates were compared using ordinary one-way analysis
of variance (ANOVA) and Tukey’s multiple-comparison test or paired t test.
ChIP sequencing. ChIP was conducted according to protocols adapted from the ones described
previously by Cecchini et al. (49). Brieﬂy, cross-linked chromatin was sonicated so that most chromatin
was ⱕ400 bp. Sheared chromatin was then normalized between experimental groups and precleared
with protein G Dynabeads and IgG. Precleared chromatin was then incubated with protein G Dynabeads
and ChIP antibodies to immunoprecipitate proteins. Antibodies raised against ␥H2AX (clone JBW301;
EMD Millipore) and H4 (clone 62-141-13; EMD Millipore) were used for ChIP. Cross-links were reversed at
65°C, and samples were treated with RNase and proteinase K. DNA was isolated for library preparation,
and 20 replicates per genotype for ␥H2AX ChIP-Seq were pooled to achieve the DNA yield required for
library preparation (NEBNext Ultra II DNA library prep kit). ChIP libraries were sequenced using an
Illumina NextSeq system (high-output 75-cycle kit).
The resulting FASTQ reads were aligned to human genome build hg19 using Bowtie2 version
2.3.0 (50). The following command was used: bowtie2 -t -p 4 -D 15 -R 2 -L 32 -i S,1,0.75 -x hg19 -U
⬍reads⬎.fastq -S ⬍output⬎.sam. Peaks were identiﬁed using MACS2 version macs2 2.1.1.20160309,
according to parameters stated below and with the options to detect broad peak distributions for
histone marks (32). For H4 ChIP-Seq, the corresponding inputs were used as the control, and for
␥H2AX ChIP-Seq, the ﬁrst input replicate was used as the control. The following command was used:
macs2 callpeak -t ⬍ChIP⬎.bam -c ⬍input⬎.bam -n ⬍output⬎ – outdir ./macs2/-g hs – broad
– broad-cutoff 0.1.
To ﬁnd the abundance of ChIP-Seq reads in common fragile sites (CFS), the cytogenetically determined locations of CFS, as determined previously by Lukusa and Fryns, were converted to human
genomic coordinates (hg19) using the UCSC Genome Browser (51, 52). Bedtools coverage was then used
to ﬁnd the number of alignments for each ChIP-Seq sample within the individual CFS (53). The
abundances of reads that mapped to CFS were then converted to proportions by dividing by the total
number of mapped reads. The proportion data were further normalized against the input control, and
ratios were then made by comparing the mutant proportions to the wild-type proportions. A two-tailed
one-sample t test was performed to test if the normalized mean read count proportions for the RB1⫹/⫺
and the RB1⫺/⫺ ChIP-Seq assays at each of the CFS are equal to the normalized read count proportions
of the corresponding CFS from the wild-type control. A multitest correction was applied to the calculated
P values (using the “fdr” method from the “p.adjust” function in R). Statistical analysis of sequence data
was performed using R (version 3.4.2), and the plotting function used was lattice (v0.20-35).
For repeat analysis, another set of alignments was performed. For this analysis, reads were mapped
using Bowtie version 1.2.1.1 with high stringency to the hg19 genome (54). The following command was
used: bowtie -S – best -m 1 – chunkmbs 500 -p 4 -t – un ⬍not_aligned_unique⬎ –max ⬍multiple_reads_
unique⬎ hg19 ⬍reads⬎.fastq ⬍output⬎.sam. All remaining reads were mapped to repeat-containing
indices using previously reported methods (55), with indices also being derived from the Repbase and
Tandem Repeats Databases (56, 57). For these remaining repeat alignments, the –m 1 parameter of the
Bowtie mapping was changed to – k 1. Finally, all remaining reads were remapped to hg19 at low
stringency to exhaustively match sequence tags to the mouse genome. The abundances of sequence
tags that mapped to nonunique regions of the genome were compared by using log2 ratios of
␥H2AX-precipitable tags per million mapped reads in the mutant versus the wild type and converted into
heat maps using matrix2png (58). To test for the signiﬁcance of enrichment of reads mapped to various
repeat categories, the same analysis to test for signiﬁcance within CFS was used (see above).
Flow cytometry. Cells were plated on 6-cm plates at a density of 100,000 cells per plate. Approximately 24 h later, cells were pulsed with BrdU for a duration of 30 min. Cell cycle analysis was then carried
out as previously described (39).
Nucleoside supplementation. For nucleoside complementation, cells were seeded at a density of
50,000 cells per 6-cm plate for ﬂow cytometry and at 25,000 cells per 6-well plate with glass coverslips
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for immunoﬂuorescence. Approximately 24 h after seeding of cells, medium was replaced, either with or
without the addition of nucleosides. To prepare nucleosides, uridine (Sigma) and cytidine (Sigma) were
dissolved in autoclaved Milli-Q water to make 10 mM stocks, while adenosine (Sigma) and guanosine
(Sigma) were dissolved to make 2 mM stocks. The suspensions were brieﬂy boiled, ﬁlter sterilized, and
added to complete medium at a ﬁnal concentration of either 50 M or 10 M. Forty-eight hours after
nucleoside addition, cells were either ﬁxed for ␥H2AX IF using nonconfocal microscopy and Focinator (as
above) or ﬁxed for ﬂow cytometry. For analysis of DNA content by ﬂow cytometry, propidium iodidestained DNA content was analyzed.
Measurement of reactive oxygen species. Cells were plated in 96-well plates at a density of
1,200 cells per well in DMEM without phenol red (catalog number 31053-028; Thermo Fisher
Scientiﬁc). H2O2 was added 24 h after seeding of cells. Seventy-two hours later, 5(6)-carboxy-2=,7=dichlorodihydroﬂuorescein diacetate (carboxy-H2DCFDA; CA-DCF-DA) (catalog number C400;
Thermo Fisher Scientiﬁc) at a stock concentration of 20 mM in dimethyl sulfoxide (DMSO) was
diluted in DMEM without phenol red to a concentration of 40 M. This master mix of medium and
CA-DCF-DA was added directly to the wells already containing medium and the drug of interest, to
obtain a ﬁnal concentration of 20 M CA-DCF-DA. The cells were then placed in the incubator for
45 min, and readings were obtained using a Synergy H4 hybrid reader (BioTek, USA), using
excitation/emission wavelengths of 492 nm/525 nm. Technical triplicates were analyzed for each
biological replicate, and the average background readings (cells treated with the highest concentration of the drug of interest for 72 h and DMSO in place of CA-DCF-DA) from each cell line were
subtracted from the average of each treatment reading for analysis of ﬂuorescence.
Mouse xenografts. U2OS clones were grown in cell culture to approximately 80% conﬂuence. Cells
were washed with PBS, trypsinized, centrifuged, and washed 3 times with Hanks’ balanced salt solution
(HBSS) (1⫻). Cells were then resuspended in HBSS at a concentration of 5 ⫻ 106 cells/ml so that 200 l
contained the 1 ⫻ 106 cells required for each injection.
For subcutaneous injections, mice were approximately 8 weeks old, and for the tail vein injections,
mice were approximately 13 weeks old when injected. All mice were given at least 3 days to acclimatize.
All mice were female NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ mice (stock number 005557; The Jackson Laboratory) and were housed and handled as approved by the Canadian Council on Animal Care, under an
approved protocol (2016-068).
For subcutaneous injections, 1 ⫻ 106 RB1⫹/⫹ cells were injected into the left ﬂank of all mice, and
1 ⫻ 106 RB1⫹/⫺ or RB1⫺/⫺ cells were injected into the right ﬂank. The mice used for the subcutaneous
injections were euthanized approximately 8 weeks after injection. Necropsies were performed, and
tumor mass was determined. Tumors were then ﬁxed in formalin for 48 h and processed for histological
assessment.
For tail vein injections, 1 ⫻ 106 cells were injected into the lateral tail vein. Mice were euthanized 8 weeks
after tail vein injection. All animals were subjected to a thorough necropsy, and all lungs as well as any
abnormal tissues or organs were ﬁxed in formalin for 48 h and processed for histological assessment.
All tissues of interest from both studies were embedded, sectioned, and stained with hematoxylin
and eosin according to standard methods. Slides were imaged using an Aperio ScanScope slide scanner
(Leica Biosystems).
For quantitative pathology of lungs from tail vein-injected mice, images were analyzed using QuPath
(59). Brieﬂy, annotations were drawn around each individual lung. Within these annotated lungs, cells
were detected using the cell detection command. The features within these cells were then smoothed
by using the add smoothed features command (using 25 m as the radius). Within the lungs, regions
containing different cell types were annotated, and these annotations were used to train a cell classiﬁer.
All 67 possible cell features were then used to build the random-trees classiﬁer, using default parameters.
A script was then made to determine the total cell area of all cell types called by the classiﬁer within each
lung, and the percentages of tumor cell area were calculated from these values. Tumor cell nodules were
manually counted using the cell types determined by the classiﬁer; anything thought to have derived
from a single-cell seeding event was considered a tumor cell nodule.
To determine the RB1 genotype of seeded U2OS cells of interest, embedded mouse lung tissue was
deparafﬁnized and lysed, formalin cross-links were reversed, and DNA was isolated according to the
manufacturer’s instructions (QIAamp DNA FFPE tissue kit; Qiagen). DNA was genotyped as described
above by PCR using genotyping primers (X22F and X22R).
Data extraction from cBioPortal. Only TCGA studies used for the Pan-Cancer Atlas with 150 samples
or more on cBioPortal were selected to query (60, 61). Data from cBioPortal were obtained in January
2019. Mutation and copy number alteration (CNA) data were analyzed, with the gene set user-deﬁned
list being entered as “RB1: AMP HOMDEL HETLOSS mut.”
Data availability. Processed reads have been deposited in the GEO database (accession number
GSE125379).
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